Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) – Pipeline Review, H2 2017’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease under development targeting Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bayer AG

Bristol-Myers Squibb Co

Ionis Pharmaceuticals Inc

Mochida Pharmaceutical Co Ltd

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Overview 7

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Companies Involved in Therapeutics Development 21

Bayer AG 21

Bristol-Myers Squibb Co 21

Ionis Pharmaceuticals Inc 22

Mochida Pharmaceutical Co Ltd 22

Novartis AG 23

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Drug Profiles 24

AB-012 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

AB-022 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

BAY-1213790 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

BMS-262084 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BMS-654457 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BMS-962212 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

coagulation factor XI (human) - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

coagulation factor XI (human) - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-7041 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

IONIS-FXILRx - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

IONIS-FXIRx - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Ir-CPI - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

MAA-868 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MR-1007 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Dormant Products 43

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Product Development Milestones 44

Featured News & Press Releases 44

Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017 44

Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 44

Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 45

Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 46

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 47

May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 48

May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI 48

Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 49

Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 49

Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 50

Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 51

Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Pipeline by Bayer AG, H2 2017 21

Pipeline by Bristol-Myers Squibb Co, H2 2017 22

Pipeline by Ionis Pharmaceuticals Inc, H2 2017 22

Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017 23

Pipeline by Novartis AG, H2 2017 23

Dormant Projects, H2 2017 43

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and kRoutes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports